Late in 2007, the U.S. Food and Drug Administration (FDA) held a public meeting chaired by Dr. Randall Lutter, Deputy Commissioner for Policy, and Dr.
Late in 2007, the U.S. Food and Drug Administration (FDA) held a public of developing a behind-the-counter (BTC) status for drug access in the United States.
Administration (FDA) held a public hearing on the possibility of making certain medications available “behind-the-counter”. The purpose of the meeting was to.